Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
CNMD - CONMED Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$78.00
DETAILS
HIGH:
$95.00
LOW:
$61.00
MEDIAN:
$78.00
CONSENSUS:
$78.00
UPSIDE:
109.51%
Stock News
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (âBoardâ), effective July 1, 20
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total.
Is the Options Market Predicting a Spike in CONMED Stock?
Investors need to pay close attention to CNMD stock based on the movements in the options market lately.
CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up
CNMD tops Q1 estimates despite sales dip, lifts 2026 organic growth outlook as strategic shift sharpens focus on higher-growth segments.
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Q1 Earnings and Revenues Beat Estimates
Conmed (CNMD) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.95 per share a year ago.
CONMED Corporation Announces First Quarter 2026 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from th.
A Look at Conmed Corp (CNMD) After 3.3% Gain -- GF Value $78.09 vs Price $39.73
On April 14, 2026, Conmed Corp (CNMD) shares rose 3.3% to a current price of $39.73. The stock is trading within a 52-week range of $33.21 to $61.08, reflecting
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CNMD's high-margin platforms, supply-chain recovery and margin expansion plans support growth, though tariffs and portfolio shifts weigh on near-term results.
CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro.
CONMED Corporation (NYSE:CNMD) Given Consensus Recommendation of “Reduce” by Analysts
Shares of CONMED Corporation (NYSE: CNMD - Get Free Report) have earned an average rating of "Reduce" from the eight analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 12 month price
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.
Conmed (CNMD) Up 22.9% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.
CONMED Corporation (NYSE:CNMD) Receives Consensus Recommendation of “Reduce” from Analysts
Shares of CONMED Corporation (NYSE: CNMD - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating
CONMED Q4 Earnings Call Highlights
CONMED (NYSE: CNMD) reported fourth-quarter fiscal 2025 sales of $373.2 million, representing a 7.9% year-over-year increase as reported and 7.1% growth in constant currency, as management emphasized continued progress in orthopedics and improved supply conditions. For the full year, sales were $1.375 billion, up 5.2% as reported and 5.1% in constant currency. President and CEO Pat
CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.
Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Price Targets
Conmed price target lowered to $61 from $91 at Needham
$61.00
(was $57.19)
Mike Matson
·
Needham
Needham Reiterates Buy Rating on CONMED (CNMD)
$97.00
(was $66.59)
Mike Matson
·
Needham
CONMED (CNMD) PT Lowered to $95 at Piper Sandler
$95.00
(was $64.34)
Matt O\'Brien
·
Piper Sandler
CONMED (CNMD) PT Lowered to $107 at Needham
$107.00
(was $70.01)
Mike Matson
·
Needham
Conmed price target lowered to $108 from $118 at Piper Sandler
$108.00
(was $83.39)
Matt O'Brien
·
Piper Sandler